Elsevier

Cancer Treatment Reviews

Volume 40, Issue 10, December 2014, Pages 1221-1229
Cancer Treatment Reviews

Complications of Treatment
Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: A systematic review and meta-analysis

https://doi.org/10.1016/j.ctrv.2014.09.002Get rights and content

Highlights

  • We performed a meta-analysis to assess an infection risk with anti-EGFR monoclonal antibodies (mAbs; cetuximab, panitumumab).

  • Anti-EGFR mAbs were associated with an increased risk of high-grade infection (RR, 1.49) and febrile neutropenia (RR, 1.27).

  • The incidence of high-grade infection and febrile neutropenia due to anti-EGFR mAbs was 9.3% and 5.3%, respectively.

Abstract

Background

Clinical trials have reported a substantial variation in the risk of infection related to anti-EGFR monoclonal antibodies (mAbs) cetuximab and panitumumab. We performed a systematic review and meta-analysis to assess the infection risk in cancer patients treated with anti-EGFR mAbs.

Patients and methods

We searched PubMed and the ASCO online database of meeting abstracts up to January 2014 for relevant clinical trials. Eligible studies included randomized controlled trials (RCTs) of cetuximab and panitumumab that reported adequate safety data for grade 3–4 infection or febrile neutropenia (FN). The summary incidence, relative risk (RR) and 95% confidence intervals (CIs) were calculated.

Results

A total of 14,957 patients from 28 trials were included. Treatment with anti-EGFR mAbs was associated with an increased risk of high-grade infection (RR, 1.49; 95% CI, 1.33–1.66; P < 0.001) and FN (RR, 1.27; 95% CI, 1.09–1.48; P = 0.002). The incidence of high-grade infection and FN due to anti-EGFR mAbs was 9.3% (95% CI, 7.2–12.0%) and 5.3% (95% CI, 3.3–8.3%), respectively. A significantly increased risk of high-grade infection was observed in all subgroups analyses (type of anti-EGFR mAb, therapy of control arm and duration of treatment) except for tumor type (only colorectal cancer and non-small cell lung cancer (NSCLC) groups had the increased risk). Subgroup analyses revealed a significantly increased risk of FN in the following subgroups: cetuximab, NSCLC and treatment duration longer than the median of all trials (3.1 months).

Conclusions

The use of anti-EGFR mAbs is associated with a significantly higher risk of high-grade infection and febrile neutropenia.

Introduction

The epidermal growth factor receptor (EGFR), which is a member of the ErbB receptor tyrosine kinases, is composed of an extracellular ligand-binding domain, a hydrophobic transmembrane domain and an intracytoplasmic tyrosine kinase domain. Binding of ligands, such as epidermal growth factor (EGF) and transforming growth factor alpha (TGF-α), leads to receptor dimerization and autophosphorylation of key tyrosine residues within the receptors which initiates intracellular signaling. EGFR signaling plays an important role in cancer cell proliferation, inhibition of apoptosis, differentiation, adhesion and migration [1], [2]. Approximately 30% of cancers overexpress EGFR, which has been associated with advanced disease, recurrence, metastasis and poor survival [3], [4].

Accordingly, monoclonal antibodies (mAbs) that target the extracellular ligand-binding domain of EGFR have been developed. Cetuximab is a chimeric mAb with the Fv regions of a murine anti-EGFR antibody and human IgG1 heavy and kappa light-chain constant regions. Panitumumab is a fully human anti-EGFR mAb [5], [6]. Currently, the United States Food and Drug Administration (FDA) has approved cetuximab for the treatment of advanced/metastatic colorectal cancer and squamous cell carcinoma of the head and neck (SCCHN) [5]. Panitumumab has been approved for the treatment of patients with EGFR-expressing metastatic colorectal cancer [6].

With the use of anti-EGFR mAbs, some unique adverse events have been reported. For instance, previous meta-analyses have shown an increased risk of rash, nail changes, hypokalemia, hypomagnesemia and venous thromboembolism [7], [8], [9], [10], [11]. Additionally, infectious complications associated with anti-EGFR mAbs have been reported in randomized controlled trials (RCTs). Lee et al. performed an observational study to assess the association between cetuximab therapy and infection events requiring hospitalization. They used a national cohort of 1083 patients with head and neck cancers identified through the National Health Insurance Research Database in Taiwan. With a median follow-up duration of 6.5 months, 20.3% (32/158) patients receiving cetuximab and 10.1% (93/925) patients not receiving cetuximab had infection events. Though the propensity score analysis revealed a higher risk of infection with cetuximab (OR, 2.27; 95% CI, 1.46–3.54), the instrumental variable analysis (IVA) showed no increased risk of infection with cetuximab (OR, 0.87; 95% CI, 0.61–1.14) [12]. There were limitations to their study. First, despite their efforts to simulate the randomization situation with IVA, confounding variables may not have been adequately controlled. Second, their sample size was relatively small. Since they only included patients with head and neck cancers, we do not know its risk in other cancer types. Especially, a risk of high-grade infection with cetuximab has been reported with a substantial variation in randomized controlled trials. For instance, Pirker et al. [13] and Alberts et al. [14] reported a higher incidence of infection with cetuximab compared with control in their trials, while Sobrero et al. [15] and Lynch et al. [16] did not report a significant difference in infectious risk. RCTs have reported a risk of high-grade infection with panitumumab inconsistently as well [17], [18]. Thus, the risk of high-grade infection with anti-EGFR mAbs has not yet been fully elucidated. Therefore, we conducted an up-to-date systemic review and meta-analysis of RCTs to determine the overall risk of high-grade infection associated with the use of anti-EGFR-mAbs cetuximab and panitumumab.

Section snippets

Data source

We conducted an independent review of PubMed from January 1966 to January 2014. We limited our search to anti-EGFR monoclonal antibodies approved by the FDA. Searches were performed by using the keywords “cetuximab” or “panitumumab” and were limited to randomized clinical trials. We searched abstracts and virtual meeting presentations from the American Society of Clinical Oncology (ASCO) conferences held up to January 2014 utilizing the same search terms in order to identify relevant trials. An

Search results

Our search strategy yielded 272 potentially relevant publications in the PubMed and ASCO databases. 244 publications were excluded. This selection process and reasons for study exclusion are shown in Fig. 1. Thus, a total of 28 randomized clinical trials were considered eligible for the meta-analysis, including 16 phase III trials, 11 phase II trials and one phase II/III trial. 27 trials were open-label whereas the only one was double-blind placebo controlled. From the abstracts presented at

Discussion

This meta-analysis of 28 RCTs including a total of 14,957 patients evaluated the risk of high-grade infection and febrile neutropenia in patients with cancer receiving anti-EGFR mAbs. Our pooled results demonstrated a significantly increased risk of high-grade infection and febrile neutropenia with anti-EGFR mAbs compared with the controls with RR of 1.49 (95% CI, 1.33–1.66; P < 0.001) and RR of 1.27 (95% CI, 1.09–1.48; P = 0.002), respectively. Infection seems to be a class-type adverse effect of

Conflict of interest

The authors declare no competing financial interests.

Role of the funding source

This study was not funded by any sponsors.

Authorship

T.F. designed research, collected data, analyzed and interpreted data, and wrote the manuscript. M.S. contributed to collection of data and revision of the manuscript. K.T. participated in the elaboration of the research design and revision of the manuscript.

References (53)

  • M.M. van den Heuvel et al.

    Additional weekly cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: efficacy and safety outcomes of a randomized, multi-center phase II study investigating

    Radiother Oncol

    (2014)
  • E.S. Kim et al.

    Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial

    Lancet Oncol

    (2013)
  • D. Helbling et al.

    Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07

    Ann Oncol

    (2013)
  • J.B. Vermorken et al.

    Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

    Lancet Oncol

    (2013)
  • J.A. Sterne et al.

    Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature

    J Clin Epidemiol

    (2000)
  • M. Krampera et al.

    HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation

    Blood

    (2005)
  • P. Lewkowicz et al.

    Epidermal growth factor enhances TNF-alpha-induced priming of human neutrophils

    Immunol Lett

    (2005)
  • N.E. Hynes et al.

    ERBB receptors and cancer: the complexity of targeted inhibitors

    Nat Rev Cancer

    (2005)
  • Y. Yarden et al.

    Untangling the ErbB signalling network

    Nat Rev Mol Cell Biol

    (2001)
  • R.S. Herbst et al.

    Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy

    Cancer

    (2002)
  • G. Galizia et al.

    Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery

    Ann Surg Oncol

    (2006)
  • Bristol-Myers Squibb and Eli Lilly: Erbitux prescribing information....
  • Amgen: Vectibix prescribing information....
  • W.X. Qi et al.

    Risk of anti-EGFR monoclonal antibody-related skin rash: an up-to-date meta-analysis of 25 randomized controlled trials

    J Chemother

    (2013)
  • Y. Cao et al.

    Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancer

    Cancer Chemother Pharmacol

    (2010)
  • F. Petrelli et al.

    Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies

    Expert Opin Drug Saf

    (2012)
  • Cited by (0)

    View full text